Suppr超能文献

较高的德瑞蒂斯比值(谷草转氨酶/谷丙转氨酶)是高危非肌层浸润性膀胱癌进展的一个危险因素。

A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer.

作者信息

Fukui-Kawaura Sachi, Kawahara Takashi, Araki Yushi, Nishimura Reona, Uemura Koichi, Namura Kazuhiro, Mizuno Nobuhiko, Yao Masahiro, Uemura Hiroji, Ikeda Ichiro

机构信息

Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan.

Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.

出版信息

Oncotarget. 2021 Apr 27;12(9):917-922. doi: 10.18632/oncotarget.27944.

Abstract

BACKGROUND

High-risk non-muscle invasive bladder cancer (NMIBC) is thought to be associated with a higher risk of recurrence and progression. A recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies. This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.

MATERIALS AND METHODS

A total of 138 patients who were initially diagnosed with high-risk NMIBC between January 2012 to December 2016 were enrolled in this study. The criteria for the high-risk classification followed the EAU guidelines. The recurrence-free and progression-free survival of the higher and lower De Ritis ratio groups were compared. The cut-off value of the De Ritis ratio was set at 1.35, based on a receiver operator curve analysis.

RESULTS

The median observation period was 50.3 months. Among these patients, 32 (23.1%) patients developed recurrent disease and 15 (10.9%) patients showed progression. A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.

CONCLUSIONS

The De Ritis ratio might be a risk factor for progression in high-risk NMIBC.

摘要

背景

高危非肌层浸润性膀胱癌(NMIBC)被认为与较高的复发和进展风险相关。最近一项研究表明,高De Ritis比值是一些实体恶性肿瘤的危险因素。本研究探讨了De Ritis比值作为高危NMIBC预后标志物的重要性。

材料与方法

本研究共纳入了2012年1月至2016年12月期间最初诊断为高危NMIBC的138例患者。高危分类标准遵循欧洲泌尿外科学会(EAU)指南。比较了高De Ritis比值组和低De Ritis比值组的无复发生存率和无进展生存率。基于受试者工作特征曲线分析,将De Ritis比值的临界值设定为1.35。

结果

中位观察期为50.3个月。在这些患者中,32例(23.1%)出现复发,15例(10.9%)出现进展。多因素分析显示,非卡介苗治疗是复发的独立危险因素,而较高的De Ritis比值是癌症进展的独立危险因素。

结论

De Ritis比值可能是高危NMIBC进展的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/548d/8092343/77012caaab08/oncotarget-12-917-g001.jpg

相似文献

本文引用的文献

10
Targeting aspartate aminotransferase in breast cancer.针对乳腺癌中的天冬氨酸转氨酶
Breast Cancer Res. 2008;10(5):R84. doi: 10.1186/bcr2154. Epub 2008 Oct 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验